White Matter Pathology in Parkinson's Disease (PD)

The Role of White Matter Pathology in the Development of the Postural Instability and Gait Disturbance (PIGD) Type of Parkinson's Disease (PD)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01039831

Enrollment

120

Registered

2009-12-25

Start date

2010-01-31

Completion date

2012-01-31

Last updated

2009-12-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postural Instability Gait Disorders, White Matter Lesions

Keywords

PIGD, tremor, falls, white matter

Brief summary

The relationship between WM lesions (WM) and Postural Instability Gait Disorders (PIGD-PD)in Parkinson's disease patients is largely unknown. We hypothesize that sub-clinical WM pathology may be a major contributing factor to PIGD-PD. We will compare two groups of patients with Parkinson's disease (PD): those with PIGD and patients with dominant tremor (n=120)to assess the role of brain WM changes.

Detailed description

To compare brain WM burden using MRI in PD patients with and without PIGD. Diffusion tensor imaging (DTI) analysis techniques will be applied.We will quantify PIGD-related symptoms including cognitive function, balance and gait and their associations with MRI findings.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Diagnosis of idiopathic PD, as defined by the UK Brain Bank criteria 2. Age between 50 and 80 years 3. Hoehn and Yahr stage II-III 4. On anti-parkinsonian medications 5. Mini-Mental State Exam score ≥ 25

Exclusion criteria

1. Brain surgery in the past including implanted Deep Brain Stimulation 2. Clinically significant co-morbidities likely to affect gait e.g., acute illness, significant rheumatic, orthopedic disease, dementia, or major depression 3. Unable to walk independently 4. Inability to comply with the protocol

Countries

Israel

Contacts

Primary ContactNir Giladi, MD

ngiladi@tasmc.healht.gov.il+972-3-6974790

Backup ContactTalia Herman, MSc

talit@tasmc.health.gov.il+972-3-6974958

Outcome results